Q-omics provides the consensus-scored STXBP1 profile across patient tissues and cancer cell-line models. STXBP1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, STXBP1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, STXBP1 protein abundance shows 31,664 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, and GBM as cancer lineages where STXBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STXBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STXBP1 survival associations across molecular data types. STXBP1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STXBP1 RNA expression–survival associations across cancer types. High STXBP1 expression shows unfavorable associations in HNSC, BLCA, ACC and LUSC, but favorable associations in KIRC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for STXBP1 RNA expression.
This table summarizes STXBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for STXBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STXBP1 shows lower tumor expression in KICH, BLCA and LUAD and higher tumor expression in HNSC, COAD and READ. The HNSC box plot shows higher STXBP1 RNA expression in tumor versus normal tissue (log2 FC = +1.385, t-test p < 0.001).
This table shows molecular features associated with STXBP1 in patient tissues and cancer cell lines. In patient samples, STXBP1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, STXBP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
